Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Carcinoma, Non-Small-Cell Lung 111Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 17Recurrence 15Lymphoma 15Triple Negative Breast Neoplasms 14Neoplasms 14Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Brain Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Fulvestrant 6Letrozole 4Capecitabine 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × Vinorelbine × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡